Advertisement
Advertisement
U.S. Markets open in 7 hrs 15 mins
Advertisement
Advertisement
Advertisement
Advertisement

MiMedx Group, Inc. (MDXG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.1900+0.2500 (+6.35%)
At close: 04:00PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • A
    Alex
    Get in before the institutions gobble it up. Way too cheap.
  • j
    juiced
    MDXG in a pic
  • G
    Gynot
    Fact remains the Company is on solid ground and recurring revenues are basically funding trials. Expanded coverage for product now 100% and increasing Govt and VA ordering. To the point the stock is a pig. All biotechs are at this point unles, unless a partnership or merger comes. Then its worth 6x what is the current price. That's the truth, all others can shame the Company. Spit on the Company anything you want. It still will do in excess of $230mm in sales at 85% margin. As far as the injectible goes; we shall see. FDA is really been the drag here; not the Company.
  • E
    Elaine
    @BrianX @misrespet Do you ever review your previous posts, and expectations for this stock? I'm genuinely curious if there is such a thing as "paid pumper". Because I do think the two of you make the best possible silk purse from the sow's ear that is MDXG. I hope you are being compensated, somehow.
  • B
    BrianX
    Hmmm. So we have had a 33% bounce since hitting the low of $3.04 about two weeks ago. I did not participate unfortunately. By the way where did @PostRehab go. Wiped out all his negative assertions/posts today. Let's hope we continue to see the stock price rise continuing thru the end of the year as Japan sales news, KOA trial news and hopefully a 10-15% revenue increase takes place.
  • E
    E
    CMS changes will take effect in Q3. 2 applications max per patient. Down from 10 applications of Epifix.
    Revenue will drop 75% for Q4.
    Why is this not addressed by the leadership?
  • B
    BrianX
    So it appears Eiad (Prescience) sold about 2 million of his shares in the last month or so which of course has nothing to do with his complaining about how the stock price is going down and management should be accountable. Nothing like trying to create your own self fulfilling prophecy.
  • B
    BrianX
    Wow. Someone sold a chunk of stock in the last 15 minutes. Be interesting to see Eiad's remaining stock totals.
  • A
    Alex
    Well, that settles it. Let the management refocus on its business!
  • J
    Jennifer
    You can’t make this stuff up. Mimedx paid advisors recommend VOTE yes for all (new board members and pay) on the upcoming meeting. Wow that makes me feel better.
  • J
    Jennifer
    New CMS draft proposal for skin subs limits the applications to 2. Current limit is 10. Why is this not being addressed by management. It seems like a pretty significant impact to wound care revenue moving forward.
  • B
    BrianX
    Behrens vs Prescience Point in today's duel, who do you believe. Renowned scientist with past directorships including companies that were sold for billions, or her opponent the man out for a quick buck to save his #$%$ from angry investors. Hmmm? As a side note contrarians please note on the Stocktwits board @Winthorpe and Valentine is back spewing falsehoods and another favorite @Bobo left the board about a week ago claiming MDXG is stuck in the mud for the next few years. If you think the past repeats itself, invest now.
  • A
    Alex
    Hmm, high volume today.
  • A
    Alex
    CFO Carlson wants to increase institutional share purchase. It's currently just 32%.
    https://www.wsj.com/articles/mimedx-wants-to-draw-more-institutional-investors-after-cleaning-up-its-accounting-11654169401
  • P
    P
    Marriage is the triumph of imagination over intelligence. http://dataunion.tistory.com/19793 Never interrupt your enemy when he is making a mistake.
  • B
    Beef
    MARIETTA, Ga., June 08, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced successful regulatory approval by the Japanese Ministry of Health, Labour and Welfare (JMHLW) to market EPIFIX® in Japan.
  • B
    BrianX
    Another great presentation by management at the Canaccord Conference with again the strong implications that the Amniofix trials will come out very well. Alas, little to no movement of the stock price. Currently the stock is being priced at about its value of a wound care company, that is about 5 times its revenue divdied by shares outstanding including the convertible. One has to wonder why investors and research analysts are basically ignoring the future potential of the biological products despite the very positive nature of recent conference presentations. When all is said and done I believe the problem is that people are unwilling to accept the possibility that the company has a potential game changer. I mean in simple terns , they find it hard to believe that what literally is ground up placental discard treated by the 'Purion' process could result in a game changer for the ortho industry. That coupled with management 'errors' of the past is leading to this distrust. There is nothing we as shareholders can to to change this until results are known. Even then I wonder if the price will not seriously reflect the potential of Amniofix until the FDA gives the nod to the phase 3 OA trial. Hang in there longs!
  • J
    Jennifer
    Current management is racking in Millions and delivering 0 value to shareholders.
    Take a look at Intel and JP Morgan voting NO and those are real CEOs that actually make money!
    Prescience guy was 100% correct
  • m
    misrespet
    Our existing products are still there. When the street realizes this I expect a big stock price turn to the upside. With gaining the Japanese market and others likely $16 to $20 + is very possible with just the existing products. Yes getting the knee product approved will be in addition to my price target.
  • M
    MarketMania
    Osiris Therapeutics, Inc.
    I wonder if Russ is more knowledge than Osiris' partners - Osiris' partner - like Stryker - that knows science, sells millions, and is a WallStreet darling - do you think Stryker understands cell viability post thaw?!?! Did they do their due diligence before signing a contract with Osiris?!?

    I bet Russ is still trying to figure out if Medtronic and Zimmer even sold one dollar worth of $MDXG products! Maybe when/if they reinstate their financials, you'll see a line item for their so-calles partners. 😄

    Let me see - who do I believe?!? Russ or Stryker?!?!

    I choose Stryker!!!!

    ##### STRYKER BIO4 LITERATURE #####

    Lot tested for the presence of VEGF (vascular endothelial growth factor)

    - Ready to use out of the package; no decanting is required and thaws in 15 minutes
    - Differentiated handling compared to competition
    - Contains on average at least 600,000 cells (endogenous bone forming cells including mesenchymal stem cells, osteoprogenitors and osteoblasts) per cc
    - Lot tested for 70% cell viability post-thaw Non-immunogenic
Advertisement
Advertisement